Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001778307
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? © LIVE © TEST

Submission Contact Information

Name Phone

E-Mail Address

144: Issuer Information

Name of Issuer Akero Therapeutics, Inc.

SEC File Number 001-38944

601 Gateway Blvd.

Suite 350

Address of Issuer South San Francisco

CALIFORNIA

94080

Phone 650-487-6488

Name of Person for Whose Account the Securities are To Be Sold

Andrew Cheng

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	75000	3491250	55602175	10/02/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you Nature of Name of Is Date Amount of Date of Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	Donor Acquired	Securities Acquired	Payment	Payment *
Common	10/02/2023 St	tock Option	Issuer		75000	10/02/2023 Ca	ash

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Andrew Cheng C/o Issuer 601 Gateway Blvd. Suite 350 South San Francisco CA 94080	Common	07/03/2023	25000	1122041
Andrew Cheng C/o Issuer 601 Gateway Blvd. Suite 350 South San Francisco CA 94080	Common	08/01/2023	25000	1078867
Andrew Cheng C/o Issuer 601 Gateway Blvd. Suite 350 South San Francisco CA 94080	Common	09/01/2023	25000	1244248

144: Remarks and Signature

Remarks Options to be exercised within 3 months from the date of filing.

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on 01/10/2023

Rule 10b5-1

ATTENTION:

10/02/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for

Signature Andrew Cheng

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)